Hosted on MSN1mon
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
The study evaluated two different doses of Lumakras (960 mg daily or 240 mg daily) in combination with Vectibix versus the investigator's choice of SOC (trifluridine and tipiracil or regorafenib ...
Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer
The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRAS G12C inhibitor Lumakras as part of a ...
pharmaphorum2y
Phase 3 trial confirms Lumakras role in lung cancer
Amgen's pathfinder KRAS inhibitor Lumakras has been shown to be effective in KRAS-mutated non-small cell lung cancer (NSCLC) in a phase 3 trial that should serve as a confirmation study for its ...
pharmaphorum3d
ESMO: Amgen reveals Lumakras data as rival looms in rear-view mirror
Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in ...